{
    "clinical_study": {
        "@rank": "41901", 
        "arm_group": {
            "arm_group_label": "Sildenafil 5 mg IV, Sildenafil 10 mg IV", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Safety and tolerability of a single dose intravenous bolus injection of Sildenafil in\n      patients with moderate to severe cirrhosis and kidney disease will be determined."
        }, 
        "brief_title": "A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis", 
        "condition": "Cirrhosis", 
        "condition_browse": {
            "mesh_term": [
                "Liver Cirrhosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Subjects will be eligible for the study if they meet the following inclusion criteria:\n\n          1. Cirrhosis. Diagnosis of cirrhosis will be based on either liver biopsy OR clinical\n             characteristics (e.g. history of ascites or encephalopathy or esophageal varices or\n             gastric varices or splenomegaly or spider angioma or any clinical sign of portal\n             hypertension/cirrhosis), laboratory (e.g. history of thrombocytopenia or history of\n             APRI (Reference: Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA,\n             Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant\n             fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology\n             2003;38:518-26) [Aspartate aminotransferase (AST) to platelet ratio index] score\n             consistent with cirrhosis or history of abnormal liver function tests) and abdominal\n             imaging (Magnetic Resonance Imaging or Computed Tomography or ultrasound of the\n             abdomen) data\n\n          2. CTP Class B or C cirrhosis\n\n          3. Age 18 years or older at the time of enrollment\n\n          4. Variceal screening with an upper endoscopy within 1 year before enrollment\n\n          5. Renal dysfunction [GFR \u2265 15 and < 60 ml/min/1.73m2 estimated by 6-variable MDRD\n             equation (Reference: Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen\n             S, Kusek JW, Van Lente F. Using standardized serum creatinine values in the\n             modification of diet in renal disease study equation for estimating glomerular\n             filtration rate. Ann Intern Med 2006;145:247-54)]\n\n          6. Hemoglobin level \u2265 8 mg/dl within 4 weeks before enrollment\n\n          7. Serum sodium level \u2265 125 mmol/L within 4 weeks before enrollment\n\n        Subjects will be excluded if they have any of the following:\n\n          1. Inability to provide informed consent\n\n          2. Women who are pregnant, breast-feeding, or contemplating pregnancy\n\n          3. Treatment with organic nitrates, ritonavir, erythromycin, saquinavir, ketoconazole,\n             itraconazole, cimetidine, bosentan, rifampin, Sildenafil or any other PDE-5\n             inhibitors, alpha-blockers, and anticoagulants within 7 days before enrollment\n\n          4. Hypersensitivity or allergy to Sildenafil or any component of Sildenafil\n\n          5. Previous reaction to PDE-5 inhibitors including, but not limited to  Sildenafil,\n             Vardenafil,  Tadalafil, Avanafil (Myocardial infarction, ventricular arrhythmia,\n             sudden cardiac death, cerebrovascular hemorrhage, transient ischemic attack, stroke,\n             transient global amnesia, subarachnoid and intracerebral hemorrhages, seizure,\n             recurrence in seizures, pulmonary hemorrhage, sudden decrease of hearing, loss of\n             hearing, anxiety, prolonged erection, priapism, ocular redness, ocular burning,\n             diplopia, temporary vision loss/decreased vision, ocular swelling, ocular pressure,\n             increased intraocular pressure, retinal problems in the eye, vitreous detachment,\n             vitreous traction, paramacular edema, non-arteritic anterior ischemic optic\n             neuropathy)\n\n          6. History of untreated severe left ventricular outflow obstruction (e.g. aortic\n             stenosis, idiopathic hypertrophic subaortic stenosis)\n\n          7. History of pulmonary veno-occlusive disease\n\n          8. History of unstable angina, myocardial infarctus, life-threatening arrhythmia or\n             stroke within 6 months before enrollment\n\n          9. History of retinitis pigmentosa\n\n         10. Anatomical deformation of the penis (Peyronie's disease, angulation, cavernosal\n             fibrosis)\n\n         11. History of sickle cell anemia, multiple myeloma or leukemia\n\n         12. Renal failure treated with dialysis\n\n         13. Cognitive impairment based on IRB \"evaluation to sign consent form\"\n\n         14. Transjugular intrahepatic porto-systemic shunt placement\n\n         15. Previous kidney or liver transplantation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01954524", 
            "org_study_id": "HP-00057016"
        }, 
        "intervention": {
            "arm_group_label": "Sildenafil 5 mg IV, Sildenafil 10 mg IV", 
            "description": "Dose escalation will be performed (in different participants). The doses will be as follows:\nCTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil.", 
            "intervention_name": "Intravenous bolus injection of Sildenafil", 
            "intervention_type": "Drug", 
            "other_name": "Revatio"
        }, 
        "intervention_browse": {
            "mesh_term": "Sildenafil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21201"
                }, 
                "name": "University of Maryland, Baltimore"
            }, 
            "investigator": {
                "last_name": "Ayse L. Mindikoglu, M.D., M.P.H.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis (PATENT PENDING)", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with \"suspected adverse reaction\" of IV Sildenafil that is both \"serious\" and \"unexpected\" as a measure of safety and tolerability.", 
            "safety_issue": "Yes", 
            "time_frame": "The total time to assess the primary outcome measure will be 48 hours after Sildenafil injection (starting from Sildenafil injection time until 48 hours after Sildenafil injection)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01954524"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Maryland", 
            "investigator_full_name": "Ayse Mindikoglu", 
            "investigator_title": "Assistant Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Maryland", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Maryland", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}